NASDAQ NMS - GLOBAL MARKET · OABI
+3.10% · +$0.1400 · Vol 1.4M
Market closed · last close 4:00 PM ET · price as of 19:41:49 ET
OmniAb Inc

OmniAb Inc

Life Sciences Tools & Services
$4.61
Card
Relationship Map

Follow $OABI

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $OABI by email

Veridion Score

BETAMEDIUM CONF · 6 of 6 factors measuredMethodology
OABI
OmniAb Inc
Mon Sep 21 · last completed session · Markets closed · resumes Tue 9:30 ET
Upper range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

63/ 100
Veridion Score
Upper range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Mon Sep 21 · last completed session · Markets closed · resumes Tue 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is OABI moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading OABI catalysts
About OmniAb Inc
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Listed since
2022
Employees
89
Country
US

OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.50
Day high
$4.64
Day low
$4.45
Previous close
$4.47
52W high
$5.04
-8.56% from high
52W low
$1.36
88% of range
Market cap
$649.9M
EPS
$-0.4000
Beta
1.05
Shares out
145.4M
Volume
1.4M
0.63× rel vol
Avg volume
2.2M
VWAP
$4.57
Price history computed in-house
1W
+5.95%
1M
+6.44%
3M
+102.14%
1Y
+171.10%
YTD
+149.12%
SMA 50 $3.38 · above
SMA 200 $2.29 · above
52W position 88%

OABI overview

Veridion Score
63
Registered · 2026-09-21
6 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around OABI.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading OABI Form 4 filings
Public disclosures

Congress activity in OABI

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for OABI in the cached public ledger.

Federal contracts

OABI contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for OABI in this window.
Lobbying spend

OABI lobbying filings, year to date.

Registered lobbying filings matched to OmniAb Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for OABI in this window.
Loading news for OABI
Analyst ratings
Sovereign unlock shows live analyst consensus for OABI.
Options
Sovereign unlock shows live options positioning for OABI.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.